Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified February 2015 by DeCell Technologies Inc.
Canadian Institutes of Health Research (CIHR)
Nova Scotia Health Authority
Information provided by (Responsible Party):
Dr. Paul F. Gratzer, DeCell Technologies Inc. Identifier:
First received: July 3, 2014
Last updated: February 9, 2015
Last verified: February 2015
The purpose of this clinical trial is to perform a limited pilot study to determine the feasibility of DermGEN in the treatment of non-healing diabetic foot ulcers (DFU). This will be a one-arm prospective study. It is hypothesized that DermGEN treatment will result in positive healing outcomes with no significant adverse effects.

Condition Intervention Phase
Diabetes Type I
Diabetes Type II
Biological: DermGEN
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Feasibility Study of DermGEN Dermal Regeneration Scaffold for the Treatment of Diabetic Foot Ulcers

Resource links provided by NLM:

Further study details as provided by DeCell Technologies Inc.:

Primary Outcome Measures:
  • Mean and Median Wound Size [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion with Complete Healing [ Time Frame: 12 and 16 weeks ] [ Designated as safety issue: No ]
    Complete healing is defined as 100% epithelialization without drainage

  • Time to Complete Healing [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
    Complete healing is defined as 100% epithelialization without drainage

  • Incidence of Recurrence [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Incidence of Adverse Events [ Time Frame: 16 weeks ] [ Designated as safety issue: Yes ]
  • Wound Characterization [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Mean and Median Wound Size [ Time Frame: 16 weeks ] [ Designated as safety issue: No ]
  • Percent Change in Wound Area [ Time Frame: 4 Weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: March 2015
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: DermGEN Decellularized Dermal Matrix
DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
Biological: DermGEN
DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.

Detailed Description:
This will be a one-arm prospective study with control comparisons made to historical data for standard of care treatment of DFU's (debridement, sterile moist bandages, off-loading of the foot) obtained within the Multi-Disciplinary Leg Ulcer Clinic (MDLUC) at the QEII Hospital. This study in Halifax will be mirrored in one other participating health care center in Toronto, Ontario, Canada with each center enrolling 5-10 patients for a total of 15-20 patients.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient with documented stable Type I or II diabetes (HbA1C confirmation every 4 months)
  • Patient's ulcer is present for a minimum of 2 weeks under Investigator's care
  • Study ulcer has healed <50% in size during 2 weeks leading up to enrollment
  • Study ulcer is on plantar surface of the foot
  • Ulcer ≥1 cm2 at Day 0 of study*
  • Ulcer extends through dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone or joint capsule
  • Ulcer is free of necrotic debris and clinical infection, and is comprised of healthy vascular tissue suitable for skin grafting 2 weeks after initial presentation
  • Patient has adequate circulation to the foot as evidenced by palpable pulse
  • Ankle-Brachial Index (ABI) and Toe-Brachial Index (TBI) of ≥0.7? (mild to moderate obstruction)
  • Female patients are not pregnant at time of, or during study
  • Patient and caregiver ready and willing to participate and comply with follow-up regime
  • Patient or legal representative has read and signed the Institutional Ethics Review Board approved informed consent form

    • - ulcer usually presents as around 1 cm2 but is greater after debridement

Exclusion Criteria:

  • Evidence of gangrene on affected foot
  • Ulcer is over Charcot deformity (fractures or dislocation)
  • Ulcer is non-diabetic in etiology
  • Ulcer has tunnels or sinus tracts that cannot be completely debrided
  • Patient's HgA1C < 12
  • Medical condition(s) that in the Investigator's opinion make the patient inappropriate for study
  • Patient has/had malignant disease not in remission for 5 years or more
  • Patient has acute or chronic Hepatitis, Cirrhosis, has serum albumin <2.0 gms/dL, or has alkaline phosphatase or LDH at twice the normal upper limit
  • Patient receiving oral or parenteral corticosteroids, immunosuppression or cytotoxic agents, or is anticipated to require such agents during study
  • Patient received radiation therapy within 30 days of Day 0 of study
  • Patient has AIDS or is infected with HIV
  • Patient has participated in another study using investigational drug(s) or device within the previous 30 days
  • Obvious clinical signs and symptoms of cellulitis and osteomyelitis
  • Patient has any other conditions which seriously compromises their ability to complete the study
  • Patient has known allergies to antibiotics such as Penicillin and Streptomycin
  • Patient has history of bleeding disorder
  • Patient received elective osseous procedures to study foot with 30 days prior to screening visit
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02184455

Contact: Trish Francis, RN (902) 473-5993
Contact: Karl Conlan (902) 442-4668

Canada, Nova Scotia
Queen Elizabeth II Health Sciences Center Not yet recruiting
Halifax, Nova Scotia, Canada, B3H3A7
Principal Investigator: Mark Glazebrook, PhD, D. Sports Med., MD,FRSC         
Sub-Investigator: Jason G Williams, MD, MEd, FRCSC         
Sub-Investigator: Martin R LeBlanc, MD, FRCS(C)         
Canada, Ontario
St. Michael's Hospital Not yet recruiting
Toronto, Ontario, Canada, M5B 1W8
Contact: Ryan M Khan, CCRP    (416) 864-6060 ext 3890   
Contact: Timothy R Daniels, MD, FRSC    (416) 864-5392   
Principal Investigator: Timothy R Daniels, MD, FRSC         
Sponsors and Collaborators
Dr. Paul F. Gratzer
Canadian Institutes of Health Research (CIHR)
Nova Scotia Health Authority
Principal Investigator: Mark Glazebrook, MSc, PhD, D. Sports Med., MD Queen Elizabeth II Health Sciences Center
  More Information

Responsible Party: Dr. Paul F. Gratzer, CEO, DeCell Technologies Inc. Identifier: NCT02184455     History of Changes
Other Study ID Numbers: DeCell-001 
Study First Received: July 3, 2014
Last Updated: February 9, 2015
Health Authority: Canada: Health Canada

Keywords provided by DeCell Technologies Inc.:
Chronic Ulcer
Wound Healing

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetic Foot
Foot Ulcer
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetic Neuropathies
Foot Diseases
Autoimmune Diseases
Immune System Diseases processed this record on September 30, 2016